GLI1 and acute myeloid leukemia: Here, we demonstrate that combinatory treatment consisting of the GLI1 inhibitor GANT61 and the CDK inhibitor PD 0332991 was effective in cell lines and fresh primary patient cells, providing a novel option for treating AML in the near future.